Equities research analysts at Svb Leerink began coverage on shares of Ra Pharmaceuticals (NASDAQ:RARX) in a report issued on Wednesday, May 22nd, Marketbeat reports. The brokerage set an “outperform” rating and a $33.00 price target on the stock. Svb Leerink’s price target would indicate a potential upside of 55.22% from the stock’s current price. Svb Leerink also issued estimates for Ra Pharmaceuticals’ Q2 2019 earnings at ($0.52) EPS, Q3 2019 earnings at ($0.58) EPS, Q4 2019 earnings at ($0.65) EPS, FY2019 earnings at ($2.21) EPS and FY2020 earnings at ($2.57) EPS.
Several other equities analysts have also recently weighed in on RARX. Zacks Investment Research cut shares of Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, March 14th. BidaskClub cut shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 29th. Leerink Swann assumed coverage on shares of Ra Pharmaceuticals in a research note on Wednesday, May 22nd. They set an “outperform” rating and a $23.30 target price on the stock. Raymond James set a $49.00 target price on shares of Ra Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Finally, BMO Capital Markets set a $33.00 target price on shares of Ra Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, March 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. Ra Pharmaceuticals currently has an average rating of “Buy” and an average target price of $37.23.
RARX traded up $0.27 during midday trading on Wednesday, hitting $21.26. 405,700 shares of the company traded hands, compared to its average volume of 414,758. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.10 and a current ratio of 20.10. The stock has a market capitalization of $882.87 million, a P/E ratio of -10.34 and a beta of 0.80. Ra Pharmaceuticals has a 52 week low of $8.27 and a 52 week high of $27.68.
Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. Research analysts forecast that Ra Pharmaceuticals will post -1.98 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of the stock. Group One Trading L.P. purchased a new position in Ra Pharmaceuticals during the first quarter worth $34,000. Quantamental Technologies LLC bought a new stake in shares of Ra Pharmaceuticals during the fourth quarter worth $44,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Ra Pharmaceuticals by 163.0% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,014 shares of the company’s stock worth $68,000 after purchasing an additional 1,868 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Ra Pharmaceuticals by 57.7% during the fourth quarter. Legal & General Group Plc now owns 3,063 shares of the company’s stock worth $56,000 after purchasing an additional 1,121 shares during the last quarter. Finally, Great West Life Assurance Co. Can bought a new stake in shares of Ra Pharmaceuticals during the fourth quarter worth $63,000. 94.97% of the stock is owned by hedge funds and other institutional investors.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Featured Story: How do taxes affect a CDs total return?
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.